

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(11) Publication number : **0 618 227 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **94105075.9**

(51) Int. Cl.⁵ : **C07K 15/00, C07K 13/00,
C12N 15/12, C12N 15/18,
A61K 37/36**

(22) Date of filing : **31.03.94**

(30) Priority : **01.04.93 US 41635**

(43) Date of publication of application :
05.10.94 Bulletin 94/40

(84) Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**

(71) Applicant : **AMGEN INC.**
Amgen Center,
1840 Dehavilland Drive
Thousand Oaks, CA 91320-1789 (US)

(72) Inventor : **Thomason, Arlen R.**
2288 Watertown Court
Thousand Oaks, California 91360 (US)

(74) Representative : **Vossius, Volker, Dr. et al**
Dr. Volker Vossius
Patentanwaltskanzlei - Rechtsanwaltskanzlei
Hofbeinstrasse 5
D-81679 München (DE)

(54) **Biologically active polypeptide fusion dimers.**

(57) The present invention provides a biologically active multimeric polypeptide molecule in which two or more monomeric subunits are linked together as a single polypeptide ("fusion multimer"). These fusion multimers are more easily and rapidly refolded than unfused multimers, because the reactions necessary to generate the biologically active multimeric form of the polypeptide proceed with first order, rather than second or higher order, reaction kinetics. Fusion multimers also eliminate the simultaneous formation of undesired polypeptide by-products during refolding. The fusion multimers of the present invention specifically include PDGF fusion dimers.

EP 0 618 227 A1

Background

Human platelet-derived growth factor ("PDGF") is believed to be the major mitogenic growth factor in serum for connective tissue cells. The mitogenic activity of PDGF has been documented in numerous studies, wherein PDGF has been shown to positively affect mitogenesis in arterial smooth muscle cells, fibroblast cell lines, and glial cells. Deuel *et al.*, *J. Biol. Chem.*, 256(17), 8896-8899 (1981). See also, e.g., Heldin *et al.*, *J. Cell Physiol.*, 105, 235 (1980) (brain glial cells); Raines and Ross, *J. Biol. Chem.*, 257, 5154 (1982) (monkey arterial smooth muscle cells). PDGF is also believed to be a chemoattractant for fibroblasts, smooth muscle cells, monocytes, and granulocytes. Because of its apparent abilities to both induce mitogenesis at the site of connective tissue wounds, and to attract fibroblasts to the site of such wounds, PDGF is thought to have particular potential for therapeutic use in the repair of injured, or traumatized, connective tissues.

Other members of the PDGF family include vascular endothelial cell growth factor ("VEGF", sometimes also referred to as "vascular permeability factor, or "VPF") and placental growth factor ("PLGF"). Tischer *et al.*, *Biochem. Biophys. Res. Comm.*, 165(3), 1198-1206 (1989) and Maglione *et al.*, *Proc. Natl Acad Sci. USA*, 88, 9267-9271 (1991), respectively. Both VEGF and PLGF form disulfide bonded dimers from the eight highly conserved cysteine residues that appear in the PDGF homologous region of each monomeric unit of these PDGF family members. Tischer *et al.* and Maglione *et al.*, *ibid.* The receptors for VEGF and PLGF are also in the same receptor subfamily as the PDGF receptors. Consequently, these "newer" members of the PDGF family are thought to be potentially useful as therapeutic products in wound repair, although they have not been studied as extensively as PDGF.

Naturally occurring PDGF is a disulfide-bonded dimer having two polypeptide chains, namely the "A" and "B" chains, with the A chain being approximately 60% homologous to the B chain. Naturally occurring PDGF is found in three dimeric forms, namely PDGF-AB heterodimer, PDGF-BB homodimer, or PDGF-AA homodimer. Hannink *et al.*, *Mol. Cell Biol.*, 6, 1304-1314 (1986). Although PDGF-AB has been identified as the predominate naturally occurring form, it is the PDGF-BB homodimer that has been most widely used in wound healing studies. Each monomeric subunit of the biologically active dimer, irrespective of whether it is an A chain monomer or a B chain monomer, contains eight cysteine residues. Some of these cysteine residues form interchain disulfide bonds which hold the dimer together.

The PDGF-B found in human platelets has been identified as a 109 amino acid cleavage product (PDGF-B₁₀₉) of a 241 amino acid precursor polypeptide. Johnsson *et al.*, *EMBO Journal*, 3(5), 921-928 (1984). This 109 amino acid homologous sequence coincides with the 109 amino acid cleavage product of the *c-sis* encoded PDGF-B precursor protein and is believed by many to be the mature form of PDGF in humans. Homology with the *c-sis* encoded precursor protein begins at amino acid 82 of the 241 amino acid precursor protein and continues for 109 amino acids. Another form of PDGF-B (PDGF-B₁₁₈), corresponding to the first 119 amino acids of the *c-sis* encoded PDGF-B precursor protein, has also been identified as a major cleavage product of the *c-sis* encoded precursor protein when the entire *c-sis* gene is encoded into a transfected mammalian host. U.S. Patent No. 5,149,792. The region corresponding to amino acids 13-99 of the mature form of PDGF-B has been referred to as the "PDGF homologous region". See Tischer *et al.* and Maglione *et al.*, *ibid.*

Recombinant PDGF has been produced in mammalian, yeast and bacterial (*E. coli*) host cells. See, European Patent Publication No. 0282317 (mammalian host cells), U.S. Patent No. 4,766,073 (yeast host cells), and U.S. Patent No. 5,149,792 (*E. coli* host cells). Both mammalian and yeast host cells assemble the dimeric molecules from the monomeric subunits *in vivo*, such that the protein is expressed in its biologically active dimeric form. Bacterial host cells such as *E. coli*, on the other hand, synthesize PDGF monomers. These individual monomeric subunits must then be isolated and refolded, requiring further *in vitro* processing steps, in order to obtain the desired dimeric form of the polypeptide.

The more highly evolved mammalian and yeast host cell systems are desirable for their ability to produce multimeric polypeptides in their biologically active multimeric form, although the secretion levels of the desired recombinant product are relatively low as compared with the secretion levels of bacterial host cells. The trade-off with the higher expressing bacterial systems, such as *E. coli*, is that, in return for obtaining higher yields of recombinant product, the recombinant protein must be isolated from inclusion bodies and, in the case of a multimeric protein such as PDGF, refolded in order to generate biologically active product.

Although recently developed refolding methods, such as described in European Patent Publication no. 0460189, have increased the desirability of producing PDGF in bacterial host cells, there still remain as obstacles decreased yields during refolding (resulting from higher order reaction kinetics) and the formation of undesired polypeptide by-products where a heterodimer, or a homodimer having different analog subunits of the same PDGF chain, is refolded. (See, e.g., European Patent Publication No. 0460189, *ibid.*, wherein a PDGF-AB heterodimer formed by refolding PDGF-A and PDGF-B monomeric subunits obtained from two different transfected bacterial host cells also resulted in the formation of homodimeric PDGF-AA and PDGF-BB by-prod-

uct.)

It is an object of the present invention to provide a multimeric polypeptide having improved refolding kinetics.

It is a further object of the present invention to provide a multimeric polypeptide that can be produced recombinantly without the formation of undesired polypeptide by-products.

Summary of the Invention

The present invention provides a biologically active polypeptide molecule in which at least two monomeric polypeptide subunits of a naturally occurring multimeric protein are linked together as a single polypeptide ("fusion multimer"). The polypeptide is preferably a dimeric polypeptide from the PDGF family. The fusion multimers of the present invention are more easily and rapidly refolded than unfused multimers, because the reactions necessary to generate the biologically active multimeric form of the polypeptide proceed with first order, rather than second or higher order, reaction kinetics. The fusion multimers of the present invention also eliminate the simultaneous formation of undesired polypeptide by-products during refolding. The individual subunits of the fusion multimer of the present invention are linked together in a head to tail manner. The individual subunits may be linked together directly, or they may be separated by a spacer moiety.

The present invention also provides a method for making a biologically active fusion multimer by transfecting a host cell with a DNA sequence having the respective coding sequences of each monomeric subunit of the fusion multimer linked together in a head to tail manner to form a single continuous polypeptide.

Brief Description of the Drawings

FIG. 1 is the amino acid sequence of a PDGF fusion dimer, in which a PDGF-B₁₁₉ subunit is linked to a PDGF-B₁₀₉ subunit, separated by a spacer of amino acids -54 to -1 of the pre-pro region of the PDGF-B precursor protein.

FIG. 2 is a diagram of the steps used in construction an expression plasmid coding for the production of the PDGF-B₁₁₉B₁₀₉ fusion dimer shown in Fig. 1.

FIG. 3 is a nucleic acid coding sequence for PDGF-B₁₁₉.

FIG. 4 is a nucleic acid coding sequence for PDGF-B₁₀₉ preceded by the entire pre-pro region (81 amino acids) of the PDGF-B precursor protein.

FIG. 5 is an electrophoretic gel of the PDGF-B₁₁₉B₁₀₉ fusion dimer whose amino acid sequence is shown in Fig. 1.

FIG. 6 is a graph showing the activity of the PDGF-B₁₁₉B₁₀₉ fusion dimer as compared to PDGF-BB₁₁₉.

Detailed Description of the Invention

The present invention provides a biologically active polypeptide molecule in which at least two monomeric polypeptide subunits of a naturally occurring multimeric protein are linked together as a single polypeptide ("fusion multimer"). Preferably, the fusion multimer is a member of the PDGF family.

In order to aid in the understanding of the present invention, the following terms, as used herein, have the definitions designated below.

The terms "multimer" or "multimeric" polypeptide refer to a polypeptide molecule which, in its natural, biologically active form, contains more than one functional polypeptide subunit. The functional monomeric subunits may be covalently bonded to each other, such as through disulfide bonding, but can be separated by subjecting the multimeric polypeptide to reducing conditions, thus breaking the disulfide bonds.

The terms "dimer" or "dimeric" polypeptide refer to a polypeptide molecule which, in its natural, biologically active form, contains two functional subunits.

The terms "monomer" and "monomeric" polypeptide or "monomeric" subunit refer to a single subunit of a multimeric polypeptide. The monomeric subunit may be an exact copy of the naturally occurring monomeric subunit or it may be either a biologically active analog or a biologically inactive (inhibitor) analog. It will be appreciated that a "reduced" polypeptide will necessarily be monomeric, unless it is a fusion dimer.

The term "fusion multimer" means a polypeptide which, in its naturally occurring, biologically active form exists as a multimer, but which has been engineered to have its constituent monomeric subunits linked together, either directly, or through a spacer moiety, as a single continuous polypeptide.

The term "fusion dimer" means a polypeptide which, in its naturally occurring, biologically active form exists as a dimer, but which has been engineered to have its two constituent monomeric subunits linked together, either directly or through a spacer moiety as a single continuous polypeptide.

As used herein, the term "homodimer" refers to a dimeric molecule wherein each monomeric subunit is either the same as or is an analog of the same naturally occurring monomeric subunit. For example, PDGF is known to have several mature forms. Therefore, a PDGF-B₁₀₉B₁₁₉ dimer is considered to be a PDGF-BB homodimer even though the monomeric subunits are not exactly the same.

5 The term "spacer moiety" means a polypeptide amino acid sequence separating two monomeric subunits in a fusion multimer.

The term "biologically active" polypeptide means a polypeptide having substantially the same mitogenic, chemotactic, enzymatic and/or other detectable biological activity as the corresponding naturally occurring polypeptide.

10 The term "inhibitor" analog or "inhibitor" polypeptide means a biologically inactive polypeptide that inhibits the mitogenic, chemotactic, enzymatic and/or other detectable biological activity of the corresponding naturally occurring polypeptide.

As used herein, "refolding" means bringing a denatured, reduced or partially reduced polypeptide into a biologically active conformation. Refolding includes those instances wherein a polypeptide has been produced in denatured form and is, in fact, being brought into a biologically active conformation for the first time. The term "refolding" may be used interchangeably with "folding".

As used herein, "interchain disulfide bond" is a disulfide bond formed between two cysteine moieties of a dimeric polypeptide, wherein the cysteine moieties which form the disulfide bond are from different monomeric subunits.

20 As used herein, "intrachain disulfide bond" is a disulfide bond formed between two cysteine moieties of a dimeric polypeptide, wherein the cysteine moieties which form the disulfide bond are from the same monomeric subunit.

Unless otherwise specified, PDGF is any combination of PDGF monomers and/or dimers, including analogs thereof, reduced or unreduced, biologically active, or inactive, recombinant or otherwise. The term "PDGF" is intended to include PDGF analogs having one or more modifications to the number and/or identity of amino acid sequences of naturally occurring PDGF.

The term "PDGF homologous region" means the amino acid sequence from amino acid 13 to amino acid 99 in naturally occurring PDGF-B.

30 The term "PDGF family" means a naturally occurring dimeric polypeptide having at least about 20% amino acid sequence homology to the PDGF homologous region and having a total of eight cysteine residues within the PDGF homologous region such that the cysteine residues are highly conserved.

As used herein, cysteine residues that are "highly conserved" within the PDGF family refer to cysteine residues within the PDGF homologous region wherein no more than five adjustments, in terms of additions or deletions of numbers of amino acids, must be made in order to exactly line up the cysteine residues within the PDGF homologous sequence of a PDGF family member to the cysteine residues within the PDGF homologous region of naturally occurring PDGF B.

The term "PDGF precursor protein" refers to the entire 241 amino acid c-sis-encoded precursor protein prior to processing of the polypeptide to its shorter, mature forms (e.g., PDGF-B₁₀₉ and PDGF-B₁₁₉).

40 The term "pre-pro" region means that portion of the PDGF precursor protein which lies to the amino terminal side of the mature PDGF protein. Using the numbering system of Devare *et al.* (Devare *et al.*, *Proc. Natl Acad. Sci. USA*, 80, 732 (1983) the pre-pro region extends from amino acid -81 to amino acid -1, with the remaining amino acid sequence from 1 to 160 representing amino acids found in various mature forms of PDGF, the most common of which being PDGF-B₁₀₉ (amino acids 1-109) and PDGF-B₁₁₉ (amino acids 1-119).

45 The fusion multimer of the present invention may be any polypeptide which, in its naturally occurring, biologically active form, exists as a multimer, but which has been engineered in accordance with the teachings of the present invention to have its constituent monomeric subunits linked together, either directly, or through a spacer moiety, as a single continuous polypeptide.

50 The fusion multimers of the present invention virtually eliminate the simultaneous formation of undesired polypeptide by-products during refolding. This is particularly important where high expression bacterial host cells are used for the expression of a recombinant multimeric protein. For example, in the case where a PDGF-AB heterodimer is refolded from PDGF-A and PDGF-B monomeric subunits generated from two different *E. coli* host strains, the undesired PDGF-AA and PDGF-BB homodimeric forms must be separated from the desired PDGF-AB heterodimeric product. (European Patent Publication No. 0460189, *ibid.*) In contrast, if a PDGF-AB fusion heterodimer is expressed as a single continuous polypeptide from an *E. coli* host, in accordance with the teachings of the present invention, no such polypeptide by-products are formed. This provides a tremendous benefit in the commercial production of large quantities of multimeric proteins.

55 The same benefit can also be applicable to mammalian and yeast host cells, because these higher level expression systems have also been known to secrete undesired polypeptide by-products in certain situations

where multimeric proteins are desired. The fusion multimer of the present invention essentially eliminates the formation of these unwanted by-products.

The fusion multimers of the present invention are expected to be more easily and rapidly refolded than unfused multimers, because the reactions necessary to generate the biologically active multimeric form of the fusion polypeptide proceed with first order reaction kinetics. Unfused multimeric polypeptides, on the other hand, typically refold according to second or higher order reaction kinetics. The ability to reduce the forces necessary to bring together the two or more subunits required for refolding of the desired multimeric protein into its biologically active conformation should hasten the refolding process considerably.

The fusion multimers of the present invention can also be engineered to act as inhibitor polypeptides. This is possible, because many multimeric polypeptides function by interacting simultaneously in some way with more than one target molecule. If a fusion multimer is designed to contain at least one inhibitor analog as a monomeric subunit, the resulting multimeric inhibitor polypeptide can interact with one, but not more than one, available target molecule simultaneously. The resulting "non-productive" interaction will reduce the number of target molecules available for productive interaction with the naturally occurring biologically active form of the multimeric protein so that it cannot function to bring about its normal biological response.

An intervening region, otherwise referred to as a "spacer" or "spacer moiety", may or may not be necessary for proper folding in the case of certain fusion multimers. A spacer moiety will ordinarily be used where it is believed that the presence of a spacer will allow greater freedom for the constituent monomeric subunits of a fusion multimer to interact with each other in order to generate a biologically active form of the folded multimeric protein.

If the fusion multimer is intended for use as a human therapeutic product and a spacer moiety is desired, it is preferable to select the spacer moiety from among human polypeptides, because these polypeptide sequences will have much less of a chance of inducing an immune reaction than will a foreign polypeptide sequence. The polypeptide sequence for the spacer moiety may be any number of amino acids long, provided that the spacer moiety is not so long and cumbersome as to interfere with the necessary interaction between the constituent monomeric subunits of the fusion dimer. It will also be preferred to avoid amino acid residues that are known to interact with other residues (e.g., cysteine residues) and amino acids that are may create unusual twists or turns in an amino acid sequence.

The fusion multimer of the present invention is preferably a dimeric member of the PDGF family. More preferably, the fusion dimer is a dimeric form of PDGF, VEGF, or PLGF. Still more preferably, the fusion dimer is a dimeric form of PDGF. Most preferably, the fusion multimer of the present invention is a PDGF-BB fusion dimer. The preferred PDGF-BB fusion dimer may be a biologically active polypeptide or an inhibitor polypeptide.

In the case of a PDGF fusion dimer, a spacer moiety is not believed to be necessary. Nevertheless, if a spacer moiety is desired in the case of a PDGF fusion dimer, it will be preferable to use a spacer moiety selected from a portion of the *c-sis* encoded PDGF precursor protein. More preferably selection of the spacer moiety will be from the "pre-pro" region of the PDGF precursor protein. The pre-pro region of the PDGF precursor protein in the amino terminal end of the protein beginning with amino acid -81 and ending with amino acid -1. This is the region of the PDGF precursor protein that is usually cleaved off during processing by host cells transfected with the entire *v-sis* or *c-sis* coding sequence, and is not expected to interfere with the refolding of the PDGF fusion dimer or contribute errant properties of its own to the fusion dimer. Importantly, the pre-pro region of the PDGF precursor protein does not contain any cysteine residues.

A biologically active fusion dimer was made according to the present invention using two PDGF-B chains connected through a spacer moiety consisting of a portion of the "pre-pro" region of the PDGF B precursor protein. Although the spacer moiety is not believed to be necessary to generate a biologically active PDGF-BB fusion dimer, this particular fusion polypeptide was conveniently made from available starting materials and demonstrated biological activity.

The existence of biological activity in a fusion multimer, such as the PDGF-BB fusion dimer, demonstrated in the examples which follow, was somewhat surprising in light of the fact that there is no precedent for making a biologically active fusion dimer. Although fusion proteins (employing a highly expressing protein at the amino terminus) have been known to be effective in improving the expression of polypeptides generated for the purpose of inducing antibody response, these fusion proteins are not required to have biological activity, but merely to have epitopes for recognition by antibodies. Also, it has been suggested that the joining of two different but related proteins into a single fusion protein may result in a synergistic effect not observed when the two proteins act independently in their naturally occurring, unfused form. (Williams and Park, *Cancer*, 67, 2705-2707 (1991); granulocyte-macrophage colony-stimulating factor and interleukin-3 prepared as fusion protein). However, there is no suggestion that two monomeric subunits which must interact directly to exhibit biological activity in nature can be linked together in a single continuous polypeptide yet retain the ability to perform the

same necessary interactions required for biological activity of the resulting fusion multimer.

The present invention also provides a method for making a biologically active fusion multimer by transfecting a host cell with a DNA sequence having the respective coding sequences of each monomeric subunit of the multimeric polypeptide linked together in a head to tail manner to code for a single continuous polypeptide. (i.e., the subunits are not separated by start and stop codons.) If a spacer moiety is desired in the fusion dimer product, a coding sequence for the spacer moiety is inserted between the coding sequences for the constituent monomeric subunits.

The fusion multimer of the present invention can generally be made by any one of a number of methods known to those skilled in the art for the production of recombinant proteins. In many cases, the coding sequences for the monomeric subunits of the fusion dimer may already be available. These subunits can be easily linked together, with or without a spacer, through a DNA linker using standard linking techniques known to those skilled in the art. It is also, of course, possible to synthesize the desired fusion multimer coding sequence using a DNA sequenator. The particular method used to generate the coding sequence for the fusion dimer will ordinarily be dictated by a number of practical considerations including the availability of starting materials. Once the coding sequence for the fusion multimer product is constructed, it is inserted into a vector, with the resulting vector being used to transfect a suitable host cell using standard techniques known to those skilled in the art.

In the case of a PDGF-BB fusion homodimer, for example, one can first modify the *v-sis* gene to obtain the human counterpart *c-sis*, or use *c-sis* as a starting material. Two of the modified coding sequences are then linked together, following placement of appropriate initiation and stop codons, and inserted into a suitable vector which is then used to transfect the desired host cell.

Alternatively, one can either synthesize the PDGF-BB fusion homodimer coding sequence, or first cut back the *c-sis* gene or modified *v-sis* gene, at an appropriate restriction site near the carboxy terminus, and then rebuild the carboxy terminus of the PDGF precursor protein coding sequence to the desired end position using preferred codons for the particular vector and host cell being employed. The *c-sis* gene or modified *v-sis* gene can also be cut back at an appropriate restriction site near the amino terminus, with the amino terminus being built back to the desired starting position, again using preferred codons for the selected vector and host cell systems. In other words, any combination of synthetic methods and *in vitro* mutagenesis of naturally occurring starting materials can be used to generate fusion multimers, such as the PDGF-BB fusion dimer.

In the preferred method for generating the PDGF-BB fusion dimer of the present invention, the *v-sis* gene is modified to obtain the *c-sis* gene, otherwise referred to as the PDGF-B precursor protein coding sequence. The PDGF-B precursor protein coding sequence is then modified to obtain the desired coding sequences for the two monomeric units of the PDGF-BB fusion dimer, each of which will preferably be smaller than the entire 241 amino acid PDGF-B precursor protein. These units may be identical, or they may slightly differ. For example, it is possible to construct a PDGF-B₁₁₉B₁₀₉ fusion homodimer wherein one monomeric subunit is the 119 amino acid form of PDGF-B and the other subunit is the 109 amino acid form of PDGF-B. It will typically be preferred, but not essential, that the monomeric units of a PDGF-BB fusion homodimer begin about amino acid 1 of and end between about amino acid 109 and amino acid 119 of the PDGF precursor protein. The coding sequences for the desired two monomeric subunits are then linked together at desired locations, with or without a spacer.

The *v-sis* gene provides an excellent starting material for obtaining a precursor protein coding sequence which can then be used to generate coding sequences for the desired monomeric subunits of a PDGF-BB fusion homodimer according to the present invention. For example, in the region coding for amino acids 1-119, there are only five amino acid differences between the protein encoded by the *v-sis* gene and the *c-sis* encoded PDGF-B precursor protein. Two of these five amino acids in the *v-sis* gene can be altered by *in vitro* mutagenesis techniques to generate a DNA sequence coding for a protein in which the two amino acids are the same as the corresponding residues in the PDGF-B precursor protein. A number of methods for *in vitro* mutagenesis of DNA can be utilized for introducing the desired changes in codons 101 and 107. Such methods are well known to those skilled in the art. For example, the method of Eckstein and co-workers (Taylor *et al.*, *Nucl. Acids Res.*, 13, 8764-8785 (1985); Nakamae and Eckstein, *Nucl. Acids Res.*, 14, 9679-9698 (1986)), as described in the instruction booklet for the Amersham (Arlington Heights, Illinois) "Oligonucleotide-Directed *In Vitro* Mutagenesis System: kit, is particularly useful in converting the isoleucine residue at amino acid 101 to a threonine residue, and the alanine residue at amino acid 107 to a proline residue.

Following *in vitro* mutagenesis of amino acids 101 and 107, the altered *v-sis* DNA may then be cut back at the amino terminus with the restriction enzyme *Bgl*II, which cuts at a position corresponding to amino acid 24. The upstream portion of the gene, including the first 24 amino acids, may be restored by ligation of the downstream, *Bgl*II-cut mutagenized *v-sis* DNA with a synthetic DNA fragment encoding: (1) an ATG translation initiation codon; (2) a serine residue at amino acid 1; and, (3) the remainder of the first 24 amino acid acids of the *c-sis* encoded precursor protein. In this way, two of the other three variant amino acids, i.e., the serine

residue at amino acid 6 and the valine residue at amino acid 7, will be converted to the human PDGF-B forms (threonine and isoleucine, respectively), with the upstream precursor amino acids encoded by *v-sis* being removed.

If a PDGF-B monomeric unit longer than amino acid 113 of the PDGF-B precursor protein is desired in the PDGF-B fusion dimer, the codon at amino acid position 114 of the *v-sis* gene must also be replaced with a codon coding for the appropriate amino acid in the PDGF-B precursor protein. This can be accomplished by cutting back from the carboxy terminus of the modified *v-sis* gene in a similar manner to that used to replace the codons for amino acids 101 and 107. If the PDGF-B₁₁₉ form is desired as the second monomeric unit in the fusion dimer, the carboxy terminus can be replaced with a synthetic fragment that simultaneously alters amino acid 114 and replaces amino acid 120 with a stop codon. In this case, the mutagenized *v-sis* DNA is preferably cut with the restriction enzyme *Sma*I, which cuts at a position corresponding to amino acid 112. A synthetic DNA fragment coding for amino acids 112-119 of the PDGF-B precursor protein, and a translation stop codon at position 120 may then be ligated to the *Sma*I-cut mutagenized *v-sis* DNA. This synthetic DNA also encodes for a glycine residue, instead of a threonine residue, at amino acid 114, accomplishing the conversion of the fifth variant amino acid to the corresponding amino acid in the PDGF-B precursor protein.

To create the PDGF-BB fusion homodimer of the present invention, coding sequences for any two desired PDGF-B monomeric subunits are ligated together, with or without a spacer sequence, to generate the complete fusion dimer coding sequence. The complete coding sequence is then ligated into an appropriate expression vector, such as pCFM1156, and then transformed or transfected into an appropriate host cell system, preferably a bacterial host, such as *E. coli*. The N-terminal methionine may be removed *in vivo* following synthesis in the host cell, although some *E. coli* strains fail to remove the N-terminal methionine, thereby producing a recombinant product containing an additional amino acid residue at the amino terminus.

The preferred host cell system for production of the fusion dimer of the present invention is a bacterial host cell, preferably *E. coli*. In addition to the particular expression systems herein described, other systems are contemplated by the present invention and include, for example but without limitation, modification of the sites for protease cleavage, and/or use of an alternate leader sequence to increase the level of production of host cells of the fusion dimers of the present invention.

The therapeutic application of biologically active fusion dimers of the present invention can be used for the treatment of many types of wounds of mammalian species by physicians and/or veterinarians. The amount of biologically active PDGF used in such treatments will, of course, depend upon the severity of the wound being treated, the route of administration chosen, and the specific activity or purity of the fusion dimer, and will be determined by the attending physician or veterinarian. The term "fusion dimer therapeutically effective" amount refers to the amount of fusion dimer, in the absence of other exogenously applied growth factors, determined to produce a therapeutic response in a mammal. Such therapeutically effective amounts are readily ascertained by one of ordinary skill in the art.

The fusion dimer produced in accordance with the present invention may be administered by any route appropriate to the wound or condition being treated. Conditions which may be beneficially treated with therapeutic application(s) of PDGF fusion dimer include the aforementioned open dermal wound, dermal incisional wounds, and gastrointestinal incisional wounds. PDGF fusion dimer may also be used in the healing of bone, cartilage, tendons, ligaments, and epithelium (e.g., intestinal linings, stomach linings), and in glial repair.

Preferably, PDGF fusion dimer is applied exogenously to the wound. The exogenous application may be by a single application or dose, or by a repeated dose at multiple designated intervals. Compositions for exogenous application of the PDGF fusion dimer of the present invention are readily ascertained by one of ordinary skill in the art. It will be readily appreciated by those skilled in the art that the preferred route will vary with the wound or condition being treated. While it is possible for the PDGF fusion dimer to be administered as the pure or substantially pure compound, it is preferable to present it as a pharmaceutical formulation or preparation.

The formulations of the present invention, both for veterinary and for human use, comprise a therapeutically effective amount of PDGF as above described, together with one or more pharmaceutical acceptable carriers therefore and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Desirably, the formulation should not include oxidizing or reducing agents and other substances with which peptides are known to be incompatible. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art. All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the fusion dimer with liquid carriers or finely divided solid carriers or both.

The following examples are provided to aid in the understanding of the present invention, the true scope

of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth, without departing from the spirit of the invention.

Example 1

Construction of PDGF-B₁₁₉ Coding Sequence

A PDGF-B₁₁₉ coding sequence, shown in Fig. 3, was constructed using the *v-sis* gene as a starting material.

A. Conversion of Amino acids 101 and 102

One microgram of the plasmid pC60, a clone of the simian sarcoma virus retroviral genome (Wong-Staal *et al.*, *Science*, 213, 226-228 (1981)), was digested with restriction endonucleases *SaI* and *XbaI*, with the resulting 1183 base pair fragment then being purified by electrophoretic separation in a low melting temperature agarose gel, in accordance with the procedures described by Maniatis *et al.*, *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory (1982). The purified fragment was then excised from the gel. At the same time, 0.2 µg of M13mp19 DNA was also digested with *SaI* and *XbaI*, with the large 7245 base pair band being similarly isolated from a low melting temperature gel. Both excised gel slices were melted at 65°C, and then cooled to 37°C. All of the gel with the 7245 base pair M13mp19 fragment and one fourth of the gel with the 1183 base pair *v-sis* fragment were mixed and ligated according to Struhl, *Biotechniques*, 3, 452-453 (1985). The ligated DNA was transformed into *E. coli* K12 strain TG1, and a clear plaque was selected and grown in liquid culture. The presence of the 1183 base pair *v-sis* fragment in the M13mp19 vector was confirmed by preparation of the RF form of the phage DNA and restriction map analysis. Messing *et al.*, *Nucl. Acids Res.*, 9, 309-321 (1981).

The M13mp19/*v-sis* phage thus obtained was grown in liquid culture, and the single stranded DNA isolated. Messing *et al.*, *ibid.* This DNA was used as a template for oligonucleotide-directed *in vitro* mutagenesis to convert the amino acids at residues 101 and 107 to the corresponding amino acids of PDGF-B. *i.e.*, the ATA codon coding for isoleucine 101 was converted to ACA (coding for threonine), and the GCT codon coding for alanine 107 was converted to CCT (coding for proline).

Ten micrograms of the M13mp19/*v-sis* single-stranded DNA was annealed with 8 pmol of a phosphorylated oligonucleotide having the sequence:

5' GGTACAGGCCGTGCAGCTGCCACTGTCTCACAC 3'

This sequence is homologous to nucleotides 4283 to 4316 of the *v-sis* gene (numbering system of Devare, *ibid.*). The underlined bases of the oligonucleotide denote the changes from the *v-sis* to the human PDGF-B sequence. DNA synthesis was initiated on the mutant oligonucleotide, with the complete mutant strand being synthesized with the Klenow fragment of *E. coli* DNA polymerase I using thionucleotide triphosphates, followed by ligation with T4 DNA ligase. Any remaining single-stranded template M13mp18/*v-sis* DNA was removed by filtration on nitrocellulose filters. The non-mutant strand was nicked by incubation with restriction endonuclease III. The nicked non-mutant strand was then repolymerized with the deoxynucleotide triphosphates, using the mutant strand as a template. As a result, both DNA strands in the final product contained the desired mutations. The DNA was transformed into *E. coli* K12 strain TG1. Plaques were selected, grown in liquid culture, and the single-stranded DNA isolated. The DNA was sequenced by the method of Sanger *et al.*, *Proc. Natl. Acad. Sci. USA*, 74, 5463-5467 (1977) to confirm that the desired mutants had been obtained.

B. Conversion of Amino Acids 6 and 7

In the next step, the 5'-end of the mutated *v-sis* gene was replaced with a synthetic DNA fragment which changed amino acids 6 and 7 from the *v-sis* to the human PDGF-B forms. This synthetic fragment also provided a translation-initiating ATG codon immediately preceding the codon for serine 1 of human PDGF-B, as well as providing sequences for binding to *E. coli* ribosomes and a restriction site for ligation into the desired *E. coli* expression vector (described below). The synthetic DNA fragment was ligated to the *Bgl*II site located at nucleotide 4061 of the *v-sis* gene (numbering system of Devare *et al.*, *ibid.*). Because a *Bgl*II site which is present within the M13mp19 vector would complicate and interfere with this step, the mutated *v-sis* gene was first moved to the commercially available plasmid vector pUC18, which does not contain a *Bgl*II site. The M13mp19/*v-sis* mutant RF DNA was restricted with *SaI* and *Bam*HI, and the resulting 1193 base pair fragment

isolated by electrophoresis using a low melting temperature agarose gel. This fragment was ligated to the plasmid pUC18 which had also been restricted with *SalI* and *BamHI*. The ligated DNA was transformed into the commercially available *E. coli* K12 strain DH5 and transformants were selected by growth in the presence of ampicillin. Colonies were selected, grown in liquid culture, and isolated plasmid DNA analyzed by restriction mapping for the presence of the *v-sis* insert.

The pUC18/*v-sis* mutant DNA was restricted with *HindIII*, which cuts in the polylinker of pUC18 just upstream of the mutated *v-sis* insert, and with *BglII*, which cuts within the *v-sis* DNA at nucleotide 4061 (Numbering system of Devare *et al.*, *ibid*) corresponding to amino acid number 24 of the mature protein product. The large 3365 base pair fragment resulting from this reaction was isolated by electrophoresis in a low melting temperature agarose gel. This fragment was ligated to a synthetic double-stranded DNA fragment having the following sequence:

5' AGCTTCTAGAAGGAGGAATAACATATGTCTCTGGGTTCGTTAACCATTGCG-
3' AGATCTTCCTCCTTATTGTATACAGAGACCCAAGCAATTGGTAACGC-

-GAACCGGCTATGATTGCCGAGTGCAAGACACGAACCGAGGTGTTCTGA 3'
-CTTGGCCGATACTAACGGCTCACGTTCTGTGCTTGGCTCCACAAGCTCTAG 5'

This synthetic DNA fragment contains a *HindIII* "sticky" end at its upstream (left) end and a *BglII* "sticky" end at its downstream (right) end. In addition, an *XbaI* site (TCTAGA) is present within the synthetic DNA just downstream of the *HindIII* "sticky" end, which allows subsequent restriction with *XbaI* for ligation into the *XbaI* site of an expression vector described below. The ligated DNA was transformed into *E. coli* K12 strain DH5, with transformants being selected by growth on ampicillin-containing medium. The plasmid DNAs from resulting colonies were analyzed by restriction mapping for the presence of the synthetic DNA fragment. At this point, the pUC18/*v-sis* construction contained a mutated *v-sis* gene, with amino acid number 6, 8, 101, and 107 changed to the human PDGF form, and its 5'-end altered to begin translation with an ATG codon immediately preceding serine 1.

C. Conversion of Amino Acid 114 and Placement of a Stop Codon at Amino Acid 120

In the next step, the codon for amino acid number 114 was changed from ACT to GGT, resulting in the substitution of glycine for threonine in the final protein product. In addition, codon number 120, in which GCC codes for alanine in *v-sis*, was changed to TAA, a translation termination codon. The resulting protein product of this construction ends with the arginine at residue 119. Both of the changes were accomplished in one step by insertion of a synthetic DNA fragment after a *SmaI* site located within codon number 112.

The pUC18/*v-sis* mutant DNA generated above was restricted with *SmaI*, which cuts at nucleotide 4324 in the *v-sis* sequence (numbering system of Devare *et al.*, *ibid*), and with *EcoRI*, which cuts in the polylinker of pUC18 just downstream of the *v-sis* insert. A small fragment (510 base pairs) between the *SmaI* and *EcoRI* sites, coding for the C-terminal portion of the *v-sis* protein and a 3'-untranslated sequence, was removed by electrophoresis on a low melting temperature agarose gel. The large fragment (about 3530 base pairs) was ligated to a synthetic DNA fragment having the following sequence:

5' GGGGGGTTCCCAGGAGCAGCGATAAG 3'
3' CCCCCCAAGGGTCCTCGCTATTCCTTAA 5'

The GGT codon coding for the new glycine residue at position 114 and the TAA termination codon introduced at position 120 are underlined above. This synthetic DNA fragment contains a blunt end at its upstream (left) end and for ligating to the blunt end created by restriction of the *v-sis* mutant sequence with *SmaI*, and an *EcoRI* "sticky" end at its downstream (right) end for ligating to the *EcoRI* end created by restriction of the pUC18 polylinker with *EcoRI*. The ligated DNA was transformed into *E. coli* K12 strain DH5, with transformants being selected by growth on ampicillin-containing medium. The plasmid DNAs from resulting colonies were analyzed for the presence of the synthetic DNA fragment by restriction mapping.

Example 2Construction of PDGF-B₁₀₉ Precursor Coding Sequence

5 A PDGF-B₁₀₉ precursor coding sequence, shown in Fig. 4 and containing amino acids -84 to -1 of the pre-pro region of PDGF-B precursor protein and the first 109 amino acids of the mature PDGF-B sequence, was constructed using a combination of naturally occurring and synthetic nucleic acid sequences, with the naturally occurring *v-sis* gene being employed as a starting material.

Specifically, the PDGF-B₁₀₉ precursor coding sequence was derived as follows. The DNA from nucleotides 10 1 to 98 was a synthetic DNA fragment wherein nucleotides 1 to 5 coded for a *SacI* restriction site (for use in ligation of the completed coding sequence into a plasmid vector), and nucleotides 6-98 exactly matched the region of human PDGF-B starting with the translation-initiating ATG at amino acid -81, and ending with an in-frame *SacI* restriction site at amino acid -55.

The DNA from nucleotides 99 to 220 was derived from a *SacI* to *BstXI* fragment from the pre-pro region of *v-sis* (nucleotides 3833 to 3953 of simian sarcoma virus, Devare *et al.*, *ibid*) corresponding to amino acids 15 -54 to -13 of the PDGF-B pre-pro region. The sequence from nucleotide 221 to 269 was derived from a synthetic DNA fragment with a *BstXI* site at its upstream and a *HpaI* half-site at its downstream ends, which encoded the amino acid sequence of the human PDGF-B precursor protein from amino acid -12 to +5. The sequence from nucleotide 270 to 326 was derived from a synthetic DNA fragment, with a *HpaI* half-site at its upstream end and a *BglII* site at its downstream end, which encoded the amino acid sequence of the human PDGF-B 20 protein from amino acid +6 to amino acid +24. The sequence between nucleotides 327 and 1087 was derived from a *BglII* to *XbaI* fragment of *v-sis* (nucleotides 4225 to 4820 of simian sarcoma virus, Devare *et al.*, *ibid*) corresponding to amino acids +25 to +180 of human PDGF-B, as well as the entire 3'-untranslated region. The sequence of this latter *v-sis* fragment was altered by *in vitro* mutagenesis (as described earlier in Example 1 25 with respect to the PDGF-B₁₁₉ coding sequence) to convert nucleotide 557 from T to C, thereby converting isoleucine-101 of *v-sis* to threonine as in human PDGF-B, and to convert nucleotide 574 from G to C, thereby converting alanine-107 of *v-sis* to proline, as in human PDGF-B. *In vitro* mutagenesis was also used to convert nucleotide 583 from C to T, nucleotide 586 from A to T, nucleotide 587 from G to A, and nucleotide 588 from C to A, thereby creating two tandem translation termination codons after amino acid 109 of PDGF-B.

30 The composite DNA sequence encoding the PDGF-B precursor protein (PDGF-B₁₀₉ preceded by the entire pre-pro region of the PDGF precursor protein) was cloned as a *SacI* to *XbaI* fragment into the commercially available plasmid pGEM3. The pGEM3 plasmid contains a *SacI* restriction site just downstream of the *XbaI* site. The pGEM3/PDGF-B₁₀₉/precursor plasmid was used as a source for a *SacI* to *SacI* fragment, encoding amino acids -54 to -1 of the PDGF-B pre-pro region, amino acids 1 to 109 of the mature PDGF-B protein, and 35 the 3'-untranslated RNA sequence of *v-sis*, in constructing the PDGF-B fusion dimer DNA sequence, as described in Example 3, below.

Example 340 Construction of PDGF-B₁₁₉pre-pro/109 Plasmid in pUC18 VectorA. Insertion of PDGF-B₁₁₉ coding sequence plus synthetic joining-linker into pUC18

45 The PDGF-B₁₁₉ coding sequence from Example 1 and the PDGF-B₁₀₉ coding sequence from Example 2 were linked together through a spacer coding sequence to form a coding sequence for a PDGF-B₁₁₉B₁₀₉ fusion homodimer.

The precursor vector containing the PDGF-B₁₁₉ coding sequence was bacteriophage M13mp19. The single-stranded coding sequence was made double stranded by a standard *in vitro* reaction utilizing the Klenow fragment of *E. coli* DNA polymerase I. This double-stranded coding sequence was digested with the restriction 50 enzymes *XbaI* and *SmaI* to release an approximately 380 base pair insert containing the PDGF-B₁₁₉ coding sequence up to the *SmaI* site at amino acid 112. Thus, the DNA encoding the last 7 amino acids was absent in this DNA fragment. The fragment was purified by electrophoresis through and extraction from a Seaplaque brand low-melting temperature agarose gel. The isolated PDGF-B₁₁₉ DNA fragment was mixed with a synthetic DNA linker containing a blunt-end *SmaI* half-site at its upstream end, and a *SacI* adapter site at its downstream 55 end. The linker itself encoded amino acids 113-119 of the PDGF-B₁₁₉ monomeric unit plus amino acids number -54 and -53 of the pre-pro region of the PDGF-B precursor protein. The PDGF-B₁₁₉ DNA fragment plus the linker were ligated into the vector pUC18 which had been cut with *XbaI* and *SacI*. The ligated DNA was transformed into *E. coli* K-12 strain DH5 α . (See Fig. 2.)

Plasmid DNA was isolated from several of the resulting transformant colonies, and the DNA inserts were analyzed by agarose gel electrophoresis. One plasmid with the correct insert was identified and utilized for the next step.

5 B. Insertion of the coding sequence for the spacer moiety and PDGF-B₁₀₉ subunit downstream of PDGF-B₁₁₉ subunit coding sequence and the linker

A DNA segment encoding the amino acids number -52 to -1 of the pre-pro region of the PDGF-B precursor protein, plus amino acids number 1-109 of the mature PDGF-B sequence (PDGF-B₁₀₉), followed by two translation stop codons and the 3'-untranslated sequence of the *v-sis* gene, was inserted into the above construct at the *SacI* site. This was accomplished by first linearizing the above pUC18 construct containing the DNA encoding PDGF-B₁₁₉ and the linker with *SacI*. Next, a plasmid (pGEM3/PDGF-B₁₀₉/precursor) containing DNA coding for the entire PDGF-B precursor protein (with two stop codons following amino acid 109, so that the protein translation product was terminated after amino acid 109) was restricted with *SacI*. This restriction released a 1010 base pair fragment whose upstream end began with the codon for amino acid number -52 of the pre-pro region of the PDGF-B precursor protein, followed by the remainder of the protein coding region and the 3'-untranslated region, and whose downstream end contained part of the multiple cloning site of pGEM3. This fragment, encoding part of the pre-pro region of PDGF-B precursor protein as well as the 109 amino acid form of mature PDGF-B, was ligated into the *SacI*-cut pUC18/PDGF-B₁₁₉ construct described in Part A of this example. The ligation mixture was transformed into *E. coli* strain DH5 α , and plasmids from resulting colonies were analyzed by restriction analysis with the enzyme *Bgl*II. (See Fig. 2.)

Example 4

25 Expression of PDGF-B₁₁₉B₁₀₉ Fusion Dimer in *E. coli*

The insert in pUC18 described in Example 3, coding for the PDGF-B₁₁₉B₁₀₉ fusion dimer with a pre-pro spacer, was removed from pUC18 by restriction with *XbaI*. The 1369 base pair *XbaI* fragment was purified by electrophoresis on a Seaplaque low-melting temperature agarose gel, and ligated into the *E. coli* expression vector pCFM1156. The plasmid pCFM1156PL is prepared from the known plasmid pCFM836. The preparation of plasmid pCFM836 is described in U.S. Patent No. 4,710,473, the relevant portions of the specification, particularly examples 1 to 7, are hereby incorporated by reference. To prepare pCFM1156 and pCFM836, the two endogenous *NdeI* restriction sites are cut, the exposed ends are filled with T4 polymerase, and the filled ends are blunt-end ligated.

35 The resulting plasmid is then digested with *ClaI* and *KpnI* and the excised DNA fragment is replaced with a DNA oligonucleotide of the following sequence:

5' → 3'
 40 *ClaI* *KpnI*
 CGATTTGATTCTAGAAGGAGGAATAACATATGGTTAACGCGTTGGAATTCGGTAC
 TAAACTAAGATCTTCCTCCTTATTGTATACCAATTGCGCAACCTTAAGC
 45 3' → 5'

The pCFM1156 vector contains a region for insertion of foreign genes between an upstream *XbaI* site and one of a number of downstream restriction sites. In this case, just the *XbaI* site was utilized.

50 The ligation mixture was transformed into *E. coli* strain FM-5 (ATCC NO. 67545), and transformants were analyzed by restriction mapping. A clone containing the insert fragment in the correct orientation was identified. The DNA insert present in this plasmid was subsequently sequenced, and the observed sequence matched the expected sequence coding for the protein in Fig. 1.

55 The final expression plasmid contained an inserted DNA sequence which codes for a protein that begins with an initiating methionine, followed by amino acids 1-119 of the human PDGF-B sequence, followed by a spacer of amino acids -54 to -1 of the pre-pro region of the human PDGF-B precursor protein sequence, followed by amino acids 1-109 of the human PDGF-B sequence. The procaryotic *E. coli* host cells removed the N-terminal methionine after synthesis, so that the final protein produced corresponds to the PDGF-B₁₁₉B₁₀₉ fusion homodimer having a spacer of 54 amino acids.

The *E. coli* clone containing the insert for the PDGF-B₁₁₉B₁₀₉ fusion dimer was grown in liquid culture at 30°C for 2 hours, and then switched to the induction temperature of 42°C for 4 hours. Aliquots of the cells before and after induction were lysed by boiling in SDS, and proteins were analyzed by SDS gel electrophoresis followed by staining with Coomassie Blue dye. A band of approximately the right predicted size (31Kd) for the PDGF-B₁₁₉B₁₀₉ fusion dimer was observed in the lane derived from cells after induction, which was not present in the lane from uninduced cells. Proteins were transferred from the gel to a nitrocellulose membrane via a Western blot procedure, and the blot was analyzed by incubation with an antibody to PDGF-B. The new protein in the induced cells containing the PDGF-B₁₁₉B₁₀₉ fusion dimer plasmid specifically reacted with the antibody, confirming that this protein was in fact the PDGF-B₁₁₉B₁₀₉ fusion dimer.

Example 5

Mitogenic Activity of Unpurified PDGF-B₁₁₉B₁₀₉ Fusion Dimer

As a first test for potential mitogenic activity of the PDGF-B₁₁₉B₁₀₉ fusion dimer, *E. coli* cells expressing the protein were lysed in a French press. The insoluble material, which included most of the PDGF-B₁₁₉B₁₀₉ fusion dimer protein, was pelleted by centrifugation. The pellet was solubilized in 0.8 ml of 6 M guanidine HCl, then diluted into 8 ml of 50 mM Tris HCl, pH 8.0. It was estimated by electrophoretic analysis that this sample contained about 30 µg/ml of the PDGF-B₁₁₉B₁₀₉ fusion dimer. This material was analyzed at several concentrations for mitogenic stimulation of NRK fibroblasts. A dose-dependent stimulation was observed, with maximum stimulation occurring at a PDGF-B₁₁₉B₁₀₉ fusion dimer dose of approximately 34 ng/ml. This was the first demonstration that the protein was biologically active, and even when "folded" by this crude procedure, the level of activity was comparable to that of wild-type PDGF-BB.

Example 6

Purification and Refolding of PDGF-B₁₁₉B₁₀₉ Fusion Dimer

Cells from the *E. coli* fermentation medium of Example 5, containing PDGF-B₁₁₉B₁₀₉ fusion homodimer, were purified in two batches. In both cases, the cells were first suspended in about 10 volumes (wet weight/volume) of water, and then passed three times through a Gaulin homogenizer of 9000 psi. The homogenized cells were then centrifuged at 5000 x g for 1 hour at 4°C, and the supernatant discarded.

The resulting precipitate (inclusion bodies containing PDGF-B₁₁₉B₁₀₉ fusion homodimer) was suspended in 6 M guanidine-HCl, 100 mM Tris chloride, pH 7.5 at a volume of about 60% of the volume of water used for the first cell suspension. β-mercaptoethanol was added to a concentration of about 0.08% (v/v), and the suspension mixed for 90 minutes at ambient temperature. Five volumes of water were slowly added over about 15 minutes, mixing continued for about 16 hours at ambient temperature. Water was slowly added to bring the guanidine-HCl concentration to 0.6 M. The pH was adjusted to about 3.5 with acetic acid and mixed at 4°C for about 3 hours. The suspension was then centrifuged at 17,700 x g for 15 minutes at 4°C to clarify the mixture. The resulting supernatant was then loaded onto an S-Sepharose® column (Pharmacia Biotech, Piscataway, New Jersey) equilibrated with 0.1 M sodium acetate, pH 4. The loaded column was washed with: (1) 20 mM sodium phosphate, pH 7.5; then (2) 20 mM sodium phosphate, pH 7.5, 0.1 M sodium chloride; and then (3) 20 mM sodium phosphate, pH 7.5, 1.0 M sodium chloride.

The fractions in the last wash, containing the PDGF-B₁₁₉B₁₀₉ fusion homodimer, were pooled and applied to an immunoaffinity column containing a monoclonal antibody recognizing PDGF-BB. The loaded affinity column was washed with: (1) 0.5 M sodium chloride, 25 mM Tris-chloride, pH 7.5; and then (2) 0.5 M sodium chloride. PDGF-B₁₁₉B₁₀₉ fusion homodimer was then eluted with 1 M acetic acid, 0.15 M sodium chloride, and concentrated over an Amicon®-YM10 (Amicon, Beverly, Massachusetts) membrane solvent-exchanged with water.

The PDGF-B₁₁₉B₁₀₉ fusion homodimer was then applied to a polysulfoethyl aspartamide column (The Nest Group, South Boro, Massachusetts) and developed with a linear gradient of 0 to 1 M sodium chloride in 20 mM sodium phosphate, pH 6.8. Those fractions containing the PDGF fusion dimer were pooled, concentrated, and then exchanged into 10 mM sodium acetate, pH 4.0, 15 M sodium chloride.

Example 7

Mitogenic Activity of Purified and Folded PDGF-B₁₁₉B₁₀₉ Fusion Dimer

5 The first batch of purified PDGF-B₁₁₉B₁₀₉ fusion dimer from Example 6 was assayed for mitogenic activity on NRK cells, and was found to have activity similar to that of wild-type PDGF-BB.

10 The second batch of purified PDGF-B₁₁₉B₁₀₉ fusion dimer from Example 6 was analyzed by gel electrophoresis and for mitogenic activity on NRK cells. The protein ran as a dimer of approximately 31 Kd before and after reduction, indicating that the protein is a true fusion dimer, as shown in Fig. 5 The dose-response curves in the NRK mitogenic activity assay of the PDGF-B₁₁₉B₁₀₉ fusion dimer and of wild-type PDGF-BB homodimer were very similar, as shown in Fig. 6.

15

20

25

30

35

40

45

50

55

5

SEQUENCE LISTING

(1) GENERAL INFORMATION:

10

(i) APPLICANT:

(A) NAME: AMGEN INC.
 (B) STREET: 1840 Dehavilland Drive
 (C) CITY: Thousand Oaks
 (D) STATE: California
 (E) COUNTRY: United States of America
 (F) POSTAL CODE (ZIP): 91320-1789
 (G) TELEPHONE: 805-499-5725
 (H) TELEFAX: 805-499-8011

15

(ii) TITLE OF INVENTION: Biologically Active Polypeptide Fusion Dimers

20

(iii) NUMBER OF SEQUENCES: 11

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
 (B) COMPUTER: IBM PC compatible
 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

25

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 98 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

35 AGCTTCTAGA AGGAGGAATA ACATATGTCT CTGGGTTCGT TAACCATTCG CGAACCGGCT 60
 ATGATGCGCG AGTGCAAGAC ACGAACCGAG GGTGTGGA 98

(3) INFORMATION FOR SEQ ID NO: 2:

40

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 98 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GATCTCGAAC ACCTCGGTTT GTGTCTTGCA CTCGGCAATC ATAGCCGGTT CCGCAATGCT 60
 TAACGAACCC AGAGACATAT GTTATTCCTC CTTCTAGA 98

50

55

5
(4) INFORMATION FOR SEQ ID NO: 3:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 base pairs
 (B) TYPE: nucleic acid
10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
CGGGGGTTCC CAGGAGCAGC GATAAG 26
15
(5) INFORMATION FOR SEQ ID NO: 4:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 30 base pairs
20 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
AATTCCTATC GCTGCTCCTG GGAACCCCCC 30
25
(6) INFORMATION FOR SEQ ID NO: 5:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 55 base pairs
30 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
35 CGATTTGATT CTAGAAGGAG GAATAACATA TGGTTAACGC GTTGGGAATTC GGTAC 55
(7) INFORMATION FOR SEQ ID NO: 6:
 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 49 base pairs
40 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
45 CGAATTCCAA CGCGTTAACC ATATGTTATT CCTCCTTCTA GAATCAAAT 49
50
55

5

(8) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 387 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

10

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 20..379

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

CTAGAAGGAG GAATAACAT ATG TCT CTG GGT TCG TTA ACC ATT GCG GAA CCG	52
Met Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro	
1 5 10	
GCT ATG ATT GCC GAG TGC AAG ACA CGA ACC GAG GTG TTC GAG ATC TCC	100
Ala Met Ile Ala Glu Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser	
15 20 25	
CGG CGC CTC ATC GAC CGC ACC AAT GCC AAC TTC CTG GTG TGG CCG CCC	148
Arg Arg Leu Ile Asp Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro	
30 35 40	
TGC GTG GAG GTG CAG CGC TGC TCC GGC TGT TGC AAC AAC CGC AAC GTG	196
Cys Val Glu Val Gln Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val	
45 50 55	
CAG TGC CGG CCC ACC CAA GTG CAG CTG CGG CCA GTC CAG GTG AGA AAG	244
Gln Cys Arg Pro Thr Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys	
60 65 70 75	
ATC GAG ATT GTG CGG AAG AAG CCA ATC TTT AAG AAG GCC ACG GTG ACG	292
Ile Glu Ile Val Arg Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr	
80 85 90	
CTG GAG GAC CAC CTG GCA TGC AAG TGT GAG ACA GTG GCA GCT GCA CGG	340
Leu Glu Asp His Leu Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg	
95 100 105	
CCT GTG ACC CGA AGC CCG GGG GGT TCC CAG GAG CAG CGA TAAGAATT	387
Pro Val Thr Arg Ser Pro Gly Gly Ser Gln Glu Gln Arg	
110 115 120	

45

(9) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 120 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

55

5

Met Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu
 1 5 10 15
 10 Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp
 20 25 30
 Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln
 35 40 45
 15 Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr
 50 55 60
 Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg
 65 70 75 80
 20 Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu
 85 90 95
 Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr Arg Ser
 100 105 110
 25 Pro Gly Gly Ser Gln Glu Gln Arg
 115 120

(10) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 568 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 13..582

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

TCGACAGTCG GC ATG AAT CGC TGC TGG GCG CTC TTC CTG TCT CTC TGC 48
 Met Asn Arg Cys Trp Ala Leu Phe Leu Ser Leu Cys
 1 5 10
 40 TGC TAC CTG CGT CTG GTC AGC GCC GAG GGG GAC CCC ATT CCC GAG GAG 96
 Cys Tyr Leu Arg Leu Val Ser Ala Glu Gly Asp Pro Ile Pro Glu Glu
 15 20 25
 45 CTC TAT AAG ATG CTG AGT GGC CAC TCG ATT CGC TCC TTC GAT GAC CTC 144
 Leu Tyr Lys Met Leu Ser Gly His Ser Ile Arg Ser Phe Asp Asp Leu
 30 35 40
 CAG CGC CTG CTG CAG GGA GAC TCC GGA AAA GAA GAT GGG GCT GAG CTG 192
 Gln Arg Leu Leu Gln Gly Asp Ser Gly Lys Glu Asp Gly Ala Glu Leu
 45 50 55 60
 50 GAC CTG AAC ATG ACC CGC TCC CAT TCT GGT GGC GAG CTG GAG AGC TTG 240
 Asp Leu Asn Met Thr Arg Ser His Ser Gly Gly Glu Leu Glu Ser Leu
 65 70 75

55

5
 GCT CGT GCG AAA AGG AGC CTG GGT TCG TTA ACC ATT GCG GAA CCG GCT 288
 Ala Arg Gly Lys Arg Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala
 80 85 90

10
 ATG ATT GCC GAG TGC AAG ACA CGA ACC GAG GTG TTC GAG ATC TCC CGG 336
 Met Ile Ala Glu Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg
 95 100 105

15
 CGC CTC ATC GAC CGC ACC AAT GCC AAC TTC CTG GTG TGG CCG CCC TGC 384
 Arg Leu Ile Asp Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys
 110 115 120

20
 GTG GAG GTG CAG CGC TGC TCC GGC TGT TGC AAC AAC CGC AAC GTG CAG 432
 Val Glu Val Gln Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln
 125 130 135 140

25
 TGC CGG CCC ACC CAG GTG CAG CTG CGG CCA GTC CAG GTG AGA AAG ATC 480
 Cys Arg Pro Thr Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile
 145 150 155

30
 GAG ATT CTC CGC AAC AAC CCA ATC TTT AAG AAG GCC ACG GTG ACG CTG 528
 Glu Ile Val Arg Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu
 160 165 170

35
 GAG GAC CAC CTG GCA TGC AAG TGT GAG ACA GTG GCA GCT GCA CGG CTT 576
 Glu Asp His Leu Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro
 175 180 185

40
 GTG ACC TGATAA 588
 Val Thr
 190

(11) INFORMATION FOR SEQ ID NO: 10:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 190 amino acids
 (E) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Met Asn Arg Cys Trp Ala Leu Phe Leu Ser Leu Cys Cys Tyr Leu Arg
 1 5 10 15

45 Leu Val Ser Ala Glu Gly Asp Pro Ile Pro Glu Glu Leu Tyr Lys Met
 20 25 30

Leu Ser Gly His Ser Ile Arg Ser Phe Asp Asp Leu Gln Arg Leu Leu
 35 40 45

50 Gln Gly Asp Ser Gly Lys Glu Asp Gly Ala Glu Leu Asp Leu Asn Met
 50 55 60

55

5 Thr Arg Ser His Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg Gly Lys
 65 70 75 80
 Arg Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu
 85 90 95
 10 Cys Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp
 100 105 110
 Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln
 115 120 125
 15 Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr
 130 135 140
 Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg
 145 150 155 160
 20 Lys Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu
 165 170 175
 Ala Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr
 180 185 190

25

(12) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 232 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: unknown

30

(ii) MOLECULE TYPE: protein

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

Ser Leu Gly Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu Cys
 1 5 10 15
 Lys Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp Arg
 20 25 30
 Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln Arg
 35 40 45
 Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr Gln
 50 55 60
 Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg Lys
 65 70 75 80
 Lys Pro Ile Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu Ala
 85 90 95
 Cys Lys Cys Glu Thr Val Ala Ala Ala Arg Pro Val Thr Arg Ser Pro
 100 105 110

55

5 Gly Gly Ser Gln Glu Gln Arg Glu Leu Tyr Lys Met Leu Ser Gly His
 115 120 125
 Ser Ile Arg Ser Phe Asp Asp Leu Gln Arg Leu Leu Gln Gly Asp Ser
 130 135 140
 10 Gly Lys Glu Asp Gly Ala Glu Leu Asp Leu Asn Met Thr Arg Ser His
 145 150 155 160
 Ser Gly Gly Glu Leu Glu Ser Leu Ala Arg Gly Lys Arg Ser Leu Gly
 165 170 175
 15 Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu Cys Lys Thr Arg
 180 185 190
 Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp Arg Thr Asn Ala
 195 200 205
 20 Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln Arg Cys Ser Gly
 210 215 220
 Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro Thr Gln Val Gln Leu
 225 230 235 240
 25 Arg Pro Val Gln Val Arg Lys Ile Glu Ile Val Arg Lys Lys Pro Ile
 245 250 255
 Phe Lys Lys Ala Thr Val Thr Leu Glu Asp His Leu Ala Cys Lys Cys
 260 265 270
 30 Glu Thr Val Ala Ala Ala Arg Pro Val Thr
 275 280

35

40

45

50

55

Claims.

- 5 1. A biologically active protein comprising two or more polypeptide subunits of a naturally occurring multimeric protein wherein said subunits have been incorporated into a single continuous polypeptide.
2. The biologically active protein of claim 1 wherein each of said polypeptide subunits is a member of the PDGF family.
- 10 3. The biologically active protein of claim 2 wherein each of said polypeptide subunits comprises an amino acid sequence selected from the group consisting of PDGF-A, PDGF-B, VEGF, and PLGF amino acid sequences.
- 15 4. The biologically active protein of claim 3 wherein each of said polypeptide subunits comprises an amino acid sequence selected from the group consisting of PDGF-A and PDGF-B amino acid sequences.
5. The biologically active protein of claim 4 wherein each of said polypeptide subunits is a human PDGF-B sequence.
- 20 6. The biologically active protein of claim 1 wherein said subunits are separated from each other by a spacer moiety.
7. The biologically active protein of claim 6 wherein each of said polypeptide subunits is a member of the PDGF family.
- 25 8. The biologically active protein of claim 7 wherein each of said polypeptide subunits comprises an amino acid sequence selected from the group consisting of PDGF-A, PDGF-B, VEGF, and PLGF amino acid sequences.
- 30 9. The biologically active protein of claim 8 wherein each of said polypeptide subunits comprises an amino acid sequence selected from the group consisting of PDGF-A and PDGF-B amino acid sequences.
10. The biologically active protein of claim 9 wherein each of said polypeptide subunits is a human PDGF-B sequence.
- 35 11. The biologically active protein of claim 10 wherein one of said polypeptide subunits is PDGF-B₁₀₉ and one of said polypeptide subunits is PDGF-B₁₁₉.
- 40 12. The biologically active protein of claim 11 wherein said biologically active protein has the amino acid sequence shown in Fig. 1.
13. A coding sequence for biologically active protein comprising coding sequences for two or more polypeptide subunits of a naturally occurring multimeric protein wherein said coding sequences have been linked together to code for a single continuous polypeptide.
- 45 14. The coding sequence of claim 13 wherein said coding sequences code for a PDGF-BB fusion dimer.
15. A transfected host cell containing a coding sequence for biologically active protein comprising coding sequences for two or more polypeptide subunits of a naturally occurring multimeric protein wherein said coding sequences have been linked together to code for a single continuous polypeptide.
- 50 16. The transfected host cell of claim 15 wherein said coding sequences code for a PDGF-BB fusion dimer.
17. A pharmaceutical composition comprising a biologically active protein of claim 1 and a pharmaceutically acceptable carrier.
- 55 18. The pharmaceutical composition of claim 17 wherein said biologically active protein is a PDGF-BB fusion dimer.
19. The pharmaceutical composition of claim 18 wherein said biologically active protein has the amino acid

sequence shown in Fig. 1.

- 5 20. An inhibitor polypeptide comprising two or more polypeptide subunits of a naturally occurring multimeric protein wherein said subunits have been incorporated into a single continuous polypeptide and at least one of said subunits is biologically inactive.
21. The inhibitor polypeptide of claim 20 wherein one of said polypeptide subunits is a biologically active member of the PDGF family and one of said subunits is a biologically inactive member of the PDGF family.

10

15

20

25

30

35

40

45

50

55

SerLeuGlySerLeuThrIleAlaGluProAlaMetIleAlaGluCysLysThrArgThr
 GluValPheGluIleSerArgArgLeuIleAspArgThrAsnAlaAsnPheLeuValTrp
 ProProCysValGluValGlnArgCysSerGlyCysCysAsnArgAsnValGlnCys
 ArgProThrGlnValGlnLeuArgProValGlnValArgLysIleGluIleValArgLys
 LysProIlePheLysLysAlaThrValThrLeuGluAspHisLeuAlaCysLysCysGlu
 ThrValAlaAlaAlaArgProValThrArgSerProGlyGlySerGlnGluGlnArgGlu
LeuTyxLysMetLeuSerGlyHisSerIleArgSerPheAspLeuGlnArgLeuLeu
GlnGlyAspSerGlyLysGluAspGlyAlaGluLeuAspLeuAsnMetThrArgSerHis
SerGlyGlyGluLeuGluSerLeuAlaArgGlyLysArgSerLeuGlySerLeuThrIle
 AlaGluProAlaMetIleAlaGluCysLysThrArgThrGluValPheGluIleSerArg
 ArgLeuIleAspArgThrAsnAlaAsnPheLeuValTrpProProCysValGluValGln
 ArgCysSerGlyCysCysAsnAsnArgAsnValGlnCysArgProThrGlnValGlnLeu
 ArgProValGlnValArgLysIleGluIleValArgLysLysProIlePheLysLysAla
 ThrValThrLeuGluAspHisLeuAlaCysLysCysGluThrValAlaAlaAlaArgPro
 ValThr

FIG. 1




FIG. 2A




FIG. 2B

```

      10              30              50
1  CTAGAAGGAGGAATAACATATGCTCTCTGGGTTTCGTTAACCATTGCGGAACCGGCTATGAT
   -----+-----+-----+-----+-----+-----+-----+-----+
   TTCCTCCTTATTGTATACAGAGACCCAAGCAATTGGTAACGCCCTTGGCCGATACTA      60
   MetSerLeuGlySerLeuThrIleAlaGluProAlaMetIl
      70              90              110
61 TGCCGAGTGCAAGACACCAACCGAGGTGTTGAGATCTCCGGCGCCTCATCGACCGCAC
   -----+-----+-----+-----+-----+-----+-----+
   ACGGCTCACGTTCTGTGCTTGGCTCCACAAGCTCTAGAGGCCCGCGAGTAGCTGGCGTG      120
   eAlaGluCysLysThrArgThrGluValPheGluIleSerArgArgLeuIleAspArgTh
      14
      130              150              170
121 CAATGCCAACTTCCTGGTGTGGCGCCCTGCGTGGAGGTCCAGCGCTGCTCCGGCTGTTG
   -----+-----+-----+-----+-----+-----+-----+
   GTTACGGTTGAAGGACCACACCGCGCGGACGCACCTCCACGTCCGACGAGGCCGACAAC      180
   rAsnAlaAsnPheLeuValTrpProProCysValGluValGlnArgCysSerGlyCysCy
      34
      190              210              230
181 CAACAACCGCAACGTGCAGTGCCGGCCCAACCCAGGTGCAGCTCCGGCCAGTCCAGGTGAG
   -----+-----+-----+-----+-----+-----+-----+
   GTTGTGGCGTTGCACGTACGGCCGGGTGGGTCCACGTCCACGCCGGTCAGGTCCACTC      240
   sAsnAsnArgAsnValGlnCysArgProThrGlnValGlnLeuArgProValGlnValAr
      54
      250              270              290
241 AAAGATCGAGATTGTGCGGAACAAGCCAATCTTTAAGAAGGCCACGGTGACGCTGGAGGA
   -----+-----+-----+-----+-----+-----+-----+
   TTTCTAGCTCTAACACGCCTTCTTCGGTTAGAAATTCTTCGGTGCCACTGCGACCTCCT      300
   gLysIleGluIleValArgLysLysProIlePheLysLysAlaThrValThrLeuGluAs
      74
      310              330              350
301 CCACCTGGCATGCAAGTGTGACACAGTGGCAGCTGCACGCCCTGTGACCGGAAGCCCGGC
   -----+-----+-----+-----+-----+-----+-----+
   GGTGGACCGTACGTTACACTCTGTACCGTCCGACGTGCCGGACACTGGACTTCGGGCCC      360
   pHisLeuAlaCysLysCysGluThrValAlaAlaAlaArgProValThrArgSerProGl
      94
      370              380
361 GGGTTCCCAGGAGCAGCGATAAG
   -----+-----+-----+-----+-----+-----+-----+
   CCCAAGGGTCCTCGTCGCTATTCTTAA
   yGlySerGlnGluGlnArg
      114              1195

```

FIG. 3

10 30 50
 TCGACAGTCGGCATGAATCGCTGCTGGGCGCTCTTCTGTCTCTCTGCTGCTACCTGCCGT
 MetAsnArgCysTrpAlaLeuPheLeuSerLeuCysCysTyrLeuArg
 70 90 110
 CTGGTCAGCGCCGAGGGGGACCCCATTCCTCCGAGGAGCTCTATAAGATGCTGAGTGGCCAC
 LeuValSerAlaGluGlyAspProIleProGluGluLeuTyrLysMetLeuSerGlyHis
 130 150 170
 TCGATTCGCTCCTTCGATGACCTCCAGCGCCTGCTGCAGGGAGACTCCGGAAAAGAAGAT
 SerIleArgSerPheAspAspLeuGlnArgLeuLeuGlnGlyAspSerGlyLysGluAsp
 190 210 230
 GGGGCTGAGCTGGACCTGAACATGACCCGCTCCCATTCCTGGTGGCGAGCTGGAGAGCTTG
 GlyAlaGluLeuAspLeuAsnMetThrArgSerHisSerGlyGlyGluLeuGluSerLeu
 250 270 290
 GCTCGTGGGAAAAGGAGCCTGGGTTTCGTTAACCATTGCGGAACCGGCTATGATTGCCGAG
 AlaArgGlyLysArgSerLeuGlySerLeuThrIleAlaGluProAlaMetIleAlaGlu
 310 330 350
 TGCAAGACACGAACCGAGGTGTTTCGAGATCTCCCGGCGCCTCATCGACCGCACCAATGCC
 CysLysThrArgThrGluValPheGluIleSerArgArgLeuIleAspArgThrAsnAla
 370 390 410
 AACTTCCTGGTGTGGCCGCCCTGCGTGGAGGTGCAGCGCTGCTCCGGCTGTTGCAACAAC
 AsnPheLeuValTrpProProCysValGluValGlnArgCysSerGlyCysCysAsnAsn
 430 450 470
 CGCAACGTGCAGTGCCGGGCCACCCAGGTGCAGCTGCGGCCAGTCCAGCTGAGAAAGATC
 ArgAsnValGlnCysArgProThrGlnValGlnLeuArgProValGlnValArgLysIle
 490 510 530
 GAGATTGTGCGGAAGAAGCCAATCTTTAAGAAGGCCACGGTGACGCTGCAGGACCACCTG
 GluIleValArgLysLysProIlePheLysLysAlaThrValThrLeuGluAspHisLeu
 550 570
 GCATGCAAGTGTGAGACAGTGGCAGCTGCACGCCCTGTGACCTGATAA
 AlaCysLysCysGluThrValAlaAlaAlaArgProValThr

FIG. 4




FIG. 5




FIG. 6



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 10 5075

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
X	PROC. NATL. ACAD. SCI. USA vol. 89, July 1992 pages 6290 - 6294 QIAN, S.W. ET AL. 'Identification of the structural domain ...' * figure 1 *	1, 13, 15, 17, 20	C07K15/00 C07K13/00 C12N15/12 C12N15/18 A61K37/36
X	PROC. NATL. ACAD. SCI. USA vol. 89, April 1992 pages 3075 - 3079 BRINKMANN, U. ET AL. 'Independent domain folding of Pseudomonas exotoxin and single-chain immunotoxins ...' * figure 1 *	1, 6, 13, 15, 17, 20	
A	TIBTECH vol. 11, March 1993 pages 111 - 114 GEISOW, M.J. 'Molecular couturiers and designer proteins' * whole disclosure *	1-21	
Y	EP-A-0 325 224 (ZYMOGENETICS) 26 July 1989 * col. 4, line 7 - col. 5; col. 10, lines 25 - 56 *	1-21	
Y	EP-A-0 225 579 (G.D. SEARLE & CO.) 16 June 1987 * pages 4 - 5 *	1-21	
A	EP-A-0 259 632 (ZYMOGENETICS) 16 March 1988		
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 11 July 1994	Examiner Hermann, R
CATEGORY OF CITED DOCUMENTS		Y : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document X : particularly relevant if taken alone V : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document	

EPO FORM 180 (04/94) (P/0001)